Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069822 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01069822 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 46 participants.
The verdict
NCT01069822, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect repeated doses of AZD6765 (a drug being developed for the treatment of patients with severe major depressive disorder) has on the PK (pharmacokinetic) profile of Midazolam. (The PK profile is how the drug leaves your body and acts in the body.)
Interventions
- DRUG midazolam
- DRUG AZD6765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01069822
The ClinicalTrials.gov registry entry for NCT01069822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which midazolam is the first listed.
NCT01069822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01069822 about?
NCT01069822 is a clinical study titled "A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels". The main purpose of this study is to evaluate the effect repeated doses of AZD6765 (a drug being developed for the treatment of patients with severe major depressive disorder) has on the PK (pharmacokinetic) profile of Midazolam. (The PK profile is how the drug leaves your body and acts in the body....
What is the current status of trial NCT01069822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2010-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01069822?
The interventions under investigation include: midazolam (DRUG), AZD6765 (DRUG).
Who is sponsoring clinical trial NCT01069822?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.